Free Trial

Arvinas (ARVN) Stock Forecast & Price Target

Arvinas logo
$22.69 +1.05 (+4.85%)
(As of 11/20/2024 ET)

Arvinas - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
13

Based on 14 Wall Street analysts who have issued ratings for Arvinas in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a hold rating, and 13 have given a buy rating for ARVN.

Consensus Price Target

$61.08
169.21% Upside
According to the 14 analysts' twelve-month price targets for Arvinas, the average price target is $61.08. The highest price target for ARVN is $88.00, while the lowest price target for ARVN is $40.00. The average price target represents a forecasted upside of 169.21% from the current price of $22.69.
Get the Latest News and Ratings for ARVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Arvinas and its competitors.

Sign Up

ARVN Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
14 Buy rating(s)
14 Buy rating(s)
13 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$61.08$57.50$58.33$55.20
Forecasted Upside169.21% Upside116.41% Upside122.82% Upside157.82% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ARVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Arvinas Stock vs. The Competition

TypeArvinasMedical CompaniesS&P 500
Consensus Rating Score
2.93
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside169.21% Upside26,931.55% Upside9.81% Upside
News Sentiment Rating
Neutral News

See Recent ARVN News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/20/2024BMO Capital Markets
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$90.00 ➝ $88.00+296.57%
11/18/2024Stephens
4 of 5 stars
S. Loganathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$55.00+144.66%
10/31/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$87.00 ➝ $87.00+233.21%
10/31/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$50.00 ➝ $40.00+44.61%
9/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight
7/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$60.00 ➝ $48.00+78.44%
7/30/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$57.00 ➝ $57.00+110.41%
5/9/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$63.00 ➝ $60.00+83.43%
5/8/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$72.00 ➝ $68.00+101.06%
3/25/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$65.00+57.73%
2/22/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/14/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$36.00 ➝ $55.00+15.14%
2/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$70.00+68.67%
12/6/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$32.00 ➝ $40.00+38.07%
11/20/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$40.00+91.20%
11/13/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$32.00 ➝ $20.00+31.06%
10/23/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$70.00 ➝ $55.00+278.01%
2/24/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$81.00 ➝ $61.00+92.01%
11/22/2022Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$89.00 ➝ $74.00+71.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 06:00 AM ET.


ARVN Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Arvinas is $61.08, with a high forecast of $88.00 and a low forecast of $40.00.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There is currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARVN shares.

According to analysts, Arvinas's stock has a predicted upside of 169.21% based on their 12-month stock forecasts.

Arvinas has been rated by research analysts at BMO Capital Markets, Cantor Fitzgerald, HC Wainwright, Oppenheimer, and Stephens in the past 90 days.

Analysts like Arvinas more than other "medical" companies. The consensus rating score for Arvinas is 2.93 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ARVN compares to other companies.


This page (NASDAQ:ARVN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners